The European Ipilimumab Expanded Access Programme (EAP): Efficacy and Safety Data from the Italian Cohort of Patients with Pretreated, Advanced Melanoma
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Paola Queirolo, Francesco Cognetti(Apple (Israel)), Laura Ridolfi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Maresa Altomonte(University of Siena), Alberto Testori(IRCCS Humanitas Research Hospital), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), M.G. Bernengo(University of Turin), Federica De Galitiis(Istituto Dermopatico dell'Immacolata)
Cited by 6
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k